Skip to main content

DLBCL

6
Pipeline Programs
10
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
2
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
343%
ADC
229%
Peptide
114%
Small Molecule
114%
+ 4 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
R-pola-mini-CHPPhase 3
MSD
MSDIreland - Ballydine
1 program
1
Zilovertamab vedotinPhase 2/3ADC1 trial
Active Trials
NCT05139017Recruiting290Est. Sep 2027
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Zilovertamab vedotinPhase 2/3ADC
ETS
ETSMO - Rolla
1 program
1
IbrutinibPhase 2Small Molecule
Genmab
GenmabNetherlands - Utrecht
1 program
1
EpcoritamabPhase 1/2Monoclonal Antibody
Innovent Biologics
Innovent BiologicsChina - Jiangsu
1 program
1
IBI110 plus sintilimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05039658Unknown50Est. Dec 2022
InnoCare
InnoCareChina - Beijing
2 programs
Tafasitamab and LenalidomidePHASE_21 trial
TafasitamabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT05552937Recruiting50Est. Apr 2027
NCT06521255Recruiting244Est. Dec 2029
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Gut microbiome analysisN/A1 trial
Active Trials
NCT07498920Not Yet Recruiting30Est. Dec 2029
Teva
TevaIsrael - Petach Tikva
1 program
TL011PHASE_11 trial
Active Trials
NCT01205737Completed186Est. Sep 2013
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
DefibrotidePHASE_2Peptide1 trial
Active Trials
NCT03954106Terminated25Est. Sep 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
InnoCareTafasitamab
MSDZilovertamab vedotin
InnoCareTafasitamab and Lenalidomide
Jazz PharmaceuticalsDefibrotide
Innovent BiologicsIBI110 plus sintilimab
TevaTL011
UNION therapeuticsGut microbiome analysis

Clinical Trials (7)

Total enrollment: 875 patients across 7 trials

NCT06521255InnoCareTafasitamab

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: May 2024Est. completion: Dec 2029244 patients
Phase 3Recruiting
NCT05139017MSDZilovertamab vedotin

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Start: Jan 2022Est. completion: Sep 2027290 patients
Phase 2/3Recruiting
NCT05552937InnoCareTafasitamab and Lenalidomide

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Start: Sep 2021Est. completion: Apr 202750 patients
Phase 2Recruiting
NCT03954106Jazz PharmaceuticalsDefibrotide

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Start: Oct 2019Est. completion: Sep 202025 patients
Phase 2Terminated
NCT05039658Innovent BiologicsIBI110 plus sintilimab

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Start: Sep 2021Est. completion: Dec 202250 patients
Phase 1Unknown
NCT01205737TevaTL011

A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

Start: Sep 2010Est. completion: Sep 2013186 patients
Phase 1Completed
NCT07498920UNION therapeuticsGut microbiome analysis

Gut Microbiome in DLBCL Treated With Glofitamab

Start: Apr 2026Est. completion: Dec 202930 patients
N/ANot Yet Recruiting

Related Jobs

Specialist, Quality Assurance

Umoja BiopharmaUmoja Biopharma
Louisville, Colorado, United States
1mo ago
$85K - $105K/yr

Senior Manager, Quality Control Analytical

Umoja BiopharmaUmoja Biopharma
Louisville, Colorado, United States
1mo ago
$153K - $189K/yr

Vice President, Analytical Development

Umoja BiopharmaUmoja Biopharma
Louisville, Colorado, United States
2mo ago
$310K - $350K/yr

Senior Enterprise Systems Analyst

Umoja BiopharmaUmoja Biopharma
Louisville, Colorado, United States
2mo ago
$117K - $144K/yr

Senior Analyst, Quality Control Microbiology

Umoja BiopharmaUmoja Biopharma
Louisville, Colorado, United States
2mo ago
$71K - $88K/yr

Senior Director, Clinical Regulatory Affairs

Umoja BiopharmaUmoja Biopharma
Remote
3mo ago
$253K - $313K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 875 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.